The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain adults with relapsed or refractory multiple myeloma.
This indication of belantamab mafodotin-blmf (Blenrep, GSK) applies to adults who have received at least two prior lines of therapy that includes a proteasome inhibitor and an immunomodulatory agent.
“With the approval of Blenrep, we now have a community-accessible [B cell maturation antigen]-targeting agent with the potential to improve outcomes for patients following two or more prior lines of treatment, where options are